Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Canaccord Reiterates Buy on Edwards Lifesciences (EW); Sees Buying Opportunity
October 9, 2018 9:00 AM EDTCanaccord Genuity analyst, Jason Mills, reiterated a Buy rating and $177.00 price target on Edwards Lifesciences (NYSE: EW) following a recent pullback. Mills sees the recent weakness as a buying opportunity.
Mills thinks the post-COAPT readout for EW is extremely positive, especially given EW plans... More
